These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33942544)

  • 21. Ezh2-mediated epigenetic modification is required for allogeneic T cell-induced lupus disease.
    Zhen Y; Smith RD; Finkelman FD; Shao WH
    Arthritis Res Ther; 2020 Jun; 22(1):133. PubMed ID: 32503684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease.
    Thangavelu G; Zaiken MC; Mohamed FA; Flynn R; Du J; Rhee SY; Riddle MJ; Aguilar EG; Panoskaltsis-Mortari A; Sanders ME; Blazar BR
    Front Immunol; 2022; 13():765319. PubMed ID: 35359939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.
    Schneidawind D; Baker J; Pierini A; Buechele C; Luong RH; Meyer EH; Negrin RS
    Blood; 2015 May; 125(22):3491-500. PubMed ID: 25795920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Tedder TF; Fujimoto M
    Blood; 2013 Apr; 121(16):3274-83. PubMed ID: 23422748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-Y Aggravates Murine Chronic Graft-
    Wan L; Jin Z; Hu B; Lv K; Lei L; Liu Y; Song Y; Zhu Y; Gong H; Xu M; Du Y; Xu Y; Liu H; Wu D; Liu Y
    Front Immunol; 2020; 11():559740. PubMed ID: 33329519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune modulation and chronic graft-versus-host disease.
    Soiffer R
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S66-S69. PubMed ID: 18724307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
    Yang K; Fan ZP; Liu QF; Zhang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival.
    Rubio MT; Moreira-Teixeira L; Bachy E; Bouillié M; Milpied P; Coman T; Suarez F; Marcais A; Sibon D; Buzyn A; Caillat-Zucman S; Cavazzana-Calvo M; Varet B; Dy M; Hermine O; Leite-de-Moraes M
    Blood; 2012 Sep; 120(10):2144-54. PubMed ID: 22730537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Host-residual invariant NK T cells attenuate graft-versus-host immunity.
    Haraguchi K; Takahashi T; Matsumoto A; Asai T; Kanda Y; Kurokawa M; Ogawa S; Oda H; Taniguchi M; Hirai H; Chiba S
    J Immunol; 2005 Jul; 175(2):1320-8. PubMed ID: 16002737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention.
    Gaidot A; Landau DA; Martin GH; Bonduelle O; Grinberg-Bleyer Y; Matheoud D; Grégoire S; Baillou C; Combadière B; Piaggio E; Cohen JL
    Blood; 2011 Mar; 117(10):2975-83. PubMed ID: 21193693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models.
    Wolf D; Bader CS; Barreras H; Copsel S; Pfeiffer BJ; Lightbourn CO; Altman NH; Komanduri KV; Levy RB
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote
    Jahnke S; Schmid H; Secker KA; Einhaus J; Duerr-Stoerzer S; Keppeler H; Schober-Melms I; Baur R; Schumm M; Handgretinger R; Bethge W; Kanz L; Schneidawind C; Schneidawind D
    Front Immunol; 2019; 10():1542. PubMed ID: 31354710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner.
    McDonald-Hyman C; Flynn R; Panoskaltsis-Mortari A; Peterson N; MacDonald KP; Hill GR; Luznik L; Serody JS; Murphy WJ; Maillard I; Munn DH; Turka LA; Koreth J; Cutler CS; Soiffer RJ; Antin JH; Ritz J; Blazar BR
    Blood; 2016 Aug; 128(7):1013-7. PubMed ID: 27385791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Age Related Differences in the Biology of Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation".
    Cuvelier GDE; Li A; Drissler S; Kariminia A; Abdossamadi S; Rozmus J; Chanoine JP; Ng B; Mostafavi S; Brinkman RR; Schultz KR
    Front Immunol; 2020; 11():571884. PubMed ID: 33193355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-transplant donor CD4
    Rubio MT; Bouillié M; Bouazza N; Coman T; Trebeden-Nègre H; Gomez A; Suarez F; Sibon D; Brignier A; Paubelle E; Nguyen-Khoc S; Cavazzana M; Lantz O; Mohty M; Urien S; Hermine O
    Leukemia; 2017 Apr; 31(4):903-912. PubMed ID: 27740636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation.
    Mavers M; Maas-Bauer K; Negrin RS
    Front Immunol; 2017; 8():900. PubMed ID: 28824628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives.
    Ikegawa S; Matsuoka KI
    Front Immunol; 2021; 12():713358. PubMed ID: 34526990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.